Genomic summary statistics and meta-analysis for set-based gene environment interaction tests in large-scale sequencing studies

3 Xinyu Wang, Duy T. Pham, Kenneth E. Westerman, Cong Pan, Alisa K. Manning & Han Chen*

| 4 | Abstract |
|----|--|
| 5 | We propose an efficient method to generate the summary statistics for set-based gene-environment |
| 6 | interaction tests, as well as a meta-analysis approach that aggregates the summary statistics across |
| 7 | different studies, which can be applied to large biobank-scale sequencing studies with related samples. |
| 8 | Simulations showed that meta-analysis is numerically concordant with the equivalent pooled analysis |
| 9 | using individual-level data. Moreover, meta-analysis accommodates heterogeneity between studies and |
| 10 | enhances power in multi-ethnic studies. We applied the meta-analysis approach to the whole-exome |
| 11 | sequencing data from the UK Biobank and successfully identified gene regions associated with waist-hip |
| 12 | ratio, as well as those with sex-specific genetic effects. |
| 13 | |
| 14 | Keywords |
| 15 | Meta-analysis, genomic summary statistics, gene-environment interaction, joint test, rare variants, set- |
| 16 | based test, UK Biobank |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |

27 Background

Complex diseases are influenced by the synergy of genes and the environment. The study of gene-28 29 environment interactions (GEI) may shed light on disease etiology and help identify environmental risk 30 factors that modify the effects of disease-susceptible genes, as well as genetic variants that modify the 31 effects of environmental risk factors for complex diseases (1,2). Following rapid advances in next-32 generation sequencing (NGS) technologies over the past years, a growing body of research focuses on 33 investigating GEI effects in rare variants (with minor allele frequency (MAF) < 5%), which provides 34 insights into additional disease risk and trait variability undiscovered in common variants from genome-35 wide association studies (GWAS) (3,4). As in genetic main effect tests, single-variant tests are 36 underpowered in rare variant GEI tests (1,2). A wide variety of set-based GEI tests were developed to 37 improve the statistical power, which are commonly extensions of the burden test and sequence kernel 38 association test (SKAT) (5-7), or a combination of them (8-10). Additionally, the joint tests of both 39 genetic main effects and interaction effects for rare variants were developed to identify variants associated with complex traits, accounting for heterogeneous genetic effects in different environmental exposures 40 41 (8,10). It is especially useful to perform joint tests when the main effects are small and GEI effects are difficult to detect through interaction only tests (11,12). 42 43 Detecting rare variant GEI effects requires extremely large sample sizes given the low power as only a 44 few individuals carried a rare variant while exposed to the environment factor (2,12). Meta-analysis is a 45 well-established way to achieve the scale of sample size needed by rare variant GEI tests. By aggregating 46 summary statistics from different studies, meta-analysis not only increases the sample size, but also 47 avoids sharing individual-level data, which is usually restricted by study policies and confidentiality laws. On the other hand, the file sizes of individual-level genotype data are often extremely large, making it 48 49 difficult to transfer across platforms with limited disk space and computational resources. The meta-

50 analysis approach can circumvent this problem easily as it does not require sharing individual-level data

51 but rather the genomic summary statistics which are more resource-efficient.

52 Meta-analysis tools have been developed for genetic main effect tests (13-21). In GWAS, the widely-used 53 inverse variance weighted meta-analysis for common variants usually combines the single-variant effect estimates and their standard errors (21). Meta-analysis for rare variants cannot use the same approach, as 54 models estimating multiple genetic effect sizes with large variances for sparse data can fail to converge, 55 56 making the algorithm numerically unstable. For this reason, meta-analysis tools for rare variants usually 57 combine score statistics and covariance matrices of individual variants to recover the set-based tests, 58 which are better suited for low-frequency and rare variants. Among these tools, MetaSKAT (13), MASS 59 (17), and Meta-Qtest (19) were developed for unrelated samples. For related samples, RAREMETAL (15-60 17) can retrieve either the burden test or SKAT, whereas SMMAT (20) can recover burden, SKAT, and a unified test that combines both. 61 62 For set-based GEI tests and joint tests, however, very few meta-analysis methods have been developed. 63 Among them, of GEM (22) introduces filtering statistics based on meta-analysis, but it is only applicable 64 to unrelated samples and no joint tests for genetic main effects and GEI effects were proposed. A recent 65 study proposed extending the rareGE framework (8) to meta-analysis, which can also be conducted for 66 unrelated samples only (23). It is not computationally efficient to generate summary statistics using this 67 method, as for every variant set, a separate statistical model accounting for genetic main effects needs to 68 be fitted. Moreover, methods have been proposed for meta-analysis of joint tests for genetic main effects and GEI effects (24, 25), but they are only applicable to single variant tests. It remains a technical gap in 69 70 the field to efficiently generate and utilize genomic summary statistics for set-based GEI and joint tests. 71 Recently, we developed a computationally efficient method, Mixed-model Association test for Gene-72 Environment interactions (MAGEE), for rare variant GEI and joint tests (10). The goal of this study is to 73 develop a general framework for genomic summary statistics and meta-analysis for set-based GEI and 74 joint tests, which are applicable to both unrelated and related samples as well as both quantitative and binary traits. Since MAGEE does not require fitting a separate model adjusting for the genetic main 75 76 effects in each testing region, the genomic summary statistics for set-based GEI and joint tests can be 77 generated efficiently even for large samples in a whole-genome analysis.

78 **Results**

79 *P* value benchmark

80 The simulated individual-level genotype data included 100,000 samples and 100,000 genetic variants in 81 1,000 groups (100 variants per group). In the meta-analysis, a great amount of time can be saved when 82 the sample size is large as summary statistic-based calculations do not depend on the sample size. For 83 example, we directly computed the p values from individual-level data of 100,000 samples, which took 84 1,030 s on a single thread for each simulation replicate with 100,000 variants. In contrast, when using the 85 summary statistics, computing the p values of the same tests took only 9.7 s using a single thread on the 86 same computing server, which saved over 99% CPU time. 87 For both quantitative and binary traits with different sample sizes, we compared the p values from the meta-analysis (assuming homogeneous genetic effects across studies) with those from pooled individual-88 89 level data analysis. Each panel in Figure 1 and Figure 2 displays 10,000 p values from quantitative trait 90 analyses with related samples. In the MAGEE framework for individual-level data, we developed two GEI tests, interaction variance component (IV) test and interaction hybrid test using Fisher's method (IF), 91 92 along with three joint tests, joint variance component (JV) test, joint hybrid test using Fisher's method 93 (JF), and joint hybrid test using double Fisher's procedures (JD) (10). We conducted extensive 94 simulations in MAGEE (10), which showed that each test was well-calibrated for type I error rates. As 95 illustrating examples, here we compared results from IF test as the GEI test, and JD test as the joint test, 96 for meta-analysis and MAGEE pooled analysis. The meta-analysis assuming homogeneous genetic effects shared highly consistent empirical GEI and joint test p values with MAGEE pooled analysis (Figures 1 97 98 and 2), regardless of the simulation scenario of homogeneous or heterogeneous genetic effects, and the 99 precision of estimates increased with the sample size. Most importantly, for small p values around the 100 commonly used significance thresholds $(5.0 \times 10^{-8} \text{ to } 2.5 \times 10^{-6})$, meta-analysis did not lose any accuracy 101 compared with the MAGEE pooled analysis while being more resource-efficient in saving the 102 computational time. We also found similar results for binary traits (Supplemental Figure S1 and S2).

103

- 104 Figure 1. GEI test *p* value benchmark for meta-analysis assuming homogeneous genetic effects with
- MAGEE in 20,000, 50,000, and 100,000 unrelated samples. (A) Scenario 1 (homogeneous scenario) in
 quantitative traits. (B) Scenario 2 (heterogeneous scenario) in quantitative traits.



107

Figure 2. Joint test *p* value benchmark for meta-analysis assuming homogeneous genetic effects with
 MAGEE in 20,000, 50,000, and 100,000 unrelated samples. (A) Scenario 1 (homogeneous scenario) in





112 **Power comparison**

Figure 3 shows the empirical power of the meta-analysis GEI and joint tests for analyzing quantitative 113 114 traits from scenario 1, where the two studies had homogeneous covariate effects, genetic effects, and GEI 115 effects. The power was calculated at the significance level of 2.5×10^{-6} with 20,000, 50,000, and 100,000 116 related samples, respectively. The top panel displays results when the ratio of positive and negative causal 117 variants was 1:1, while the bottom panel displays results when the ratio of positive and negative causal 118 variants was a 4:1. Overall, the meta-analysis tests assuming homogeneous effects are more powerful for 119 both GEI and joint tests, with the IF test being more powerful than the IV test and the JF test being 120 slightly more powerful than the other 2 joint tests. 121 Figure 4 illustrated the empirical power of the meta-analysis GEI and joint tests for analyzing quantitative 122 traits from scenario 2, where the two studies had heterogeneous covariates effects, genetic effects, and 123 GEI effects. Same as in Figure 3, the ratio of positive to negative causal variants in Figure 4 was 1:1 on 124 the top panel and 4:1 on the bottom panel. In this scenario, as heterogeneity was introduced to these studies, the overall performance of the meta-analysis tests assuming heterogeneous effects outperformed 125 126 the meta-analysis assuming homogeneous effects for both GEI and joint tests. 127 The same simulations were conducted for binary traits, and we summarized those results in Supplemental 128 Figures S3 and S4.

130 Figure 3. Empirical power of meta-analysis tests for scenario 1 (homogeneous scenario) on quantitative

traits in 20,000, 50,000, and 100,000 related samples. (A) GEI tests with 80% null variants, 10% causal

variants with positive effects, and 10% causal variants with negative effects. (B) Joint tests with 80% null

variants, 10% causal variants with positive effects, and 10% causal variants with negative effects. (C) GEI

tests with 80% null variants, 16% causal variants with positive effects, and 4% causal variants with

negative effects. (D) Joint tests with 80% null variants, 16% causal variants with positive effects, and 4%causal variants with negative effects.









137

139 Figure 4. Empirical power of meta-analysis tests for scenario 2 (heterogeneous scenario) on quantitative

- traits in 20,000, 50,000, and 100,000 related samples. (A) GEI tests with 80% null variants, 10% causal
- variants with positive effects, and 10% causal variants with negative effects. (B) Joint tests with 80% null
- variants, 10% causal variants with positive effects, and 10% causal variants with negative effects. (C) GEI
- tests with 80% null variants, 16% causal variants with positive effects, and 4% causal variants with
- negative effects. (D) Joint tests with 80% null variants, 16% causal variants with positive effects, and 4%
- causal variants with negative effects.



146

147

148 Meta-analysis of waist-hip ratio in the UK Biobank

The original individual-level genotype data from whole-exome sequencing (WES) provided by the UK Biobank for 200,632 samples was 830 GB for 22 autosomes in the PLINK BED format, while the genebased summary statistics were about 11 GB in total, including 5.4 GB intermediate files from the first batch and 5.4 GB intermediate files from the second batch. By sharing only the summary statistics files

153 for meta-analysis, we saved about 98.7% disk space compared to directly sharing individual-level data for set-based GEI tests. In addition, when we directly computed *p* values from individual-level data, it took 154 155 25.48 h (91,732 s) CPU time with 10 threads to conduct all the GEI tests and joint tests in the MAGEE 156 framework. In contrast, we spent only 23.8 min (1,428 s) CPU time using a single thread on the same 157 computing server to compute the p values of the same GEI and joint tests when we had the summary 158 statistics, saving about 98.4% of computational time. One additional advantage for meta-analyzing the 159 UK Biobank WES data is that when new samples are released in future tranches, we do not have to spend 160 extra computational cost in rerunning the pooled analysis including previously released samples. Instead, 161 by combining the summary statistics from different releases in a meta-analysis, we can get similar results 162 as the pooled analysis while saving the computational resources. 163 The two batches of WES data from the UK Biobank were meta-analyzed in 18,668 protein-coding regions 164 to investigate gene-sex interactions effects on waist-hip ratio (WHR). The significance level was adjusted by Bonferroni correction for multiple testing (26) at $0.05/18,668 = 2.7 \times 10^{-6}$. As shown in Figure 5, the 165 GEI test found three significant regions: COBLL1 (p value = 5.8×10^{-10}) on chromosome 2, HMGA1 (p 166 value = 2.8×10^{-7}) on chromosome 6, and *VEGFB* (*p* value = 1.3×10^{-6}) on chromosome 11. However, none 167 of them remained significant after conditioning on significant variants in the region, defined as those with 168 a single variant joint test p value $< 5.0 \times 10^{-8}$, MAF > 1% and genotype missing rate < 5% (Table 1). A 169 170 total of 13 significant protein-coding regions were found from the joint tests, including TBX15, ACVR1C, COBLLI, NISCH, PLXND1, CYTL1, HLA-B, HMGA1, KIAA0408, MLXIPL, VEGFB, SBNO1, and 171 172 PAM16, after excluding less significant protein-coding regions in 1 million base pair flanking regions. Of note, COBLL1 (p value = 1.3×10^{-8} after adjusting for 7 significant single variants) and KIAA0408 (p 173 174 value = 9.3×10^{-9} after adjusting for 1 significant single variant) had significant joint test p values in the 175 conditional analysis (Table 1). Previous GWAS have identified many loci in these genes for WHR, some of which have sex-dimorphic 176

177 effects. For example, there is some evidence that certain loci at *COBLL1*, *PLXND1*, *HMGA1*, and *VEGFB*

178 have more impact on BMI-adjusted WHR among women (27, 28). In our meta-analysis GEI tests,

179 *PLXND1* did not show significance, however, we did identify gene-sex interactions in the other three 180 regions. Additionally, Justice et al. (29) reported gene-sex interactions in COBLL1, PLXND1, and 181 KIAA0408. There were no significant gene-sex interaction signals in PLXND1 (p value = 4.6×10^{-5}) or 182 KIAA0408 (p value = 4.5×10^{-6}), possibly because of the limited sample size in our analysis, and more 183 weights were added to rare variants using the beta function, which had potentially diminished the signals 184 from common variants. 185 We observed most signals driving our joint analyses were contributed by genetic main effects, as only 186 COBLL1, HMGA1 and VEGFB were significant in the GEI tests (they were significant in the main effect 187 tests as well). Several loci in the genes identified in the joint tests were reported to be associated with 188 WHR in previous GWAS analysis (27-32) except for HLA-B. HLA-B is a member of the human leukocyte 189 antigen (HLA) complex gene family, which helps the immune system distinguish between proteins 190 created by the body and proteins made by outside invaders like viruses and bacteria (33). Further research is needed to investigate if there are any sex-specific genetic impacts on WHR in *HLA-B*. The underlying 191 192 mechanisms for most of these genetic and sex differences have yet to be discovered. 193 We pooled individual-level data and ran MAGEE GEI and joint tests to validate the findings. 194 Supplemental Figure S5 shows that p values from the meta-analysis and the MAGEE pooled analysis 195 were highly concordant.





199 200

201 Table 1. Meta-analysis results for gene-sex interaction effects on WHR from the UK Biobank WES data analysis.

202

| | | | | Ν | N sig | Unconditional | | Condition | mal | |
|----------|-----|-----------|-----------|----------|-----------|-----------------------|-----------------------|----------------------|----------------------|--|
| Gene | Chr | Start | End | variants | variants* | GEI Joint | | GEI | Joint | |
| TBX15 | 1 | 118883046 | 118989556 | 82 | 1 | 0.79 | 5.5×10 ⁻¹¹ | 0.67 | 0.011 | |
| ACVR1C | 2 | 157526767 | 157628864 | 104 | 0 | 0.0089 | 3.1×10 ⁻⁸ | 0.0089 | 3.1×10 ⁻⁸ | |
| COBLL1 | 2 | 164653624 | 164843679 | 221 | 7 | 5.8×10 ⁻¹⁰ | 4.2×10 ⁻¹⁶ | 3.8×10 ⁻⁵ | 7.4×10 ⁻⁸ | |
| NISCH | 3 | 52455118 | 52493068 | 348 | 11 | 5.6×10 ⁻⁴ | 7.3×10 ⁻¹¹ | 5.0×10 ⁻⁴ | 3.6×10 ⁻⁴ | |
| PLXND1 | 3 | 129555175 | 129606818 | 423 | 14 | 4.6×10 ⁻⁵ | 3.0×10 ⁻¹⁵ | 0.037 | 8.3×10 ⁻⁴ | |
| CYTL1 | 4 | 5014586 | 5019458 | 33 | 0 | 0.085 | 1.6×10 ⁻⁶ | 0.085 | 1.6×10 ⁻⁶ | |
| HLA-B | 6 | 31269491 | 31357188 | 639 | 3 | 0.41 | 7.5×10 ⁻¹² | 0.45 | 2.0×10 ⁻⁵ | |
| HMGA1 | 6 | 34236873 | 34246231 | 67 | 3 | 2.8×10 ⁻⁷ | 7.3×10 ⁻²⁸ | 0.42 | 0.10 | |
| KIAA0408 | 6 | 127438406 | 127459389 | 76 | 1 | 4.5×10 ⁻⁶ | 4.4×10 ⁻¹⁷ | 0.0036 | 9.3×10 ⁻⁹ | |
| MLXIPL | 7 | 73593194 | 73624543 | 202 | 4 | 0.0014 | 5.6×10 ⁻⁸ | 0.016 | 0.0022 | |
| VEGFB | 11 | 64234538 | 64238793 | 81 | 2 | 1.3×10 ⁻⁶ | 1.2×10 ⁻¹⁷ | 0.22 | 0.16 | |
| SBNO1 | 12 | 123289109 | 123364847 | 344 | 0 | 0.021 | 1.3×10 ⁻⁸ | 0.021 | 1.3×10 ⁻⁸ | |
| PAM16 | 16 | 4331549 | 4355607 | 234 | 0 | 0.11 | 1.1×10 ⁻⁶ | 0.11 | 1.1×10 ⁻⁶ | |

203 * Number of significant variants in the region, defined as those with a single variant joint test p value <

204 5.0×10^{-8} , MAF > 1% and genotype missing rate < 5%. Conditional analysis p values were computed by

adjusting for both the genetic main effect and gene-sex interaction terms of significant single variants. 205

207 Discussion

We present a framework for meta-analysis of rare variant GEI and joint tests for continuous and binary 208 209 traits. The meta-analysis is based on a generalized linear mixed effect model (GLMM), which can 210 account for relatedness in the samples. Single-variant scores and covariance matrices of individual studies 211 can be efficiently generated from MAGEE. The summary statistics for the meta-analysis can be easily 212 aggregated, which allows combining the evidence from millions of samples collected from multiple large-213 scale sequencing studies to improve statistical power. Additionally, the proposed meta-analysis framework provides flexible set-based joint tests for genetic main effects and GEI effects, including a 214 215 SKAT-type variance component test, and two unified tests combining burden and SKAT-type tests. In 216 population-based studies, heterogeneity is possible because different ethnic groups might have different 217 MAFs or effect sizes for the same variants, as well as different levels of environmental exposure. 218 Different ways of collecting and measuring data, genotyping methods, quality-control criterion, and 219 imputation methods make studies heterogeneous (34). The meta-analysis can easily account for the 220 heterogeneity across studies, which is difficult in pooled analyses using individual-level data. 221 We evaluated the performance of the proposed GEI and joint tests through computer simulations. We first 222 showed that meta-analysis assuming homogeneous genetic effects is numerically concordant with the 223 equivalent pooled analysis using individual-level data. Additionally, the proposed methodology can 224 account for heterogeneity across studies in terms of both covariate and genetic effects. GEI and joint tests 225 assuming heterogeneous genetic effects were generally more powerful than homogeneous-type meta-226 analyses in the presence of simulated heterogeneity. Overall, IF tests were more powerful than IV tests, 227 and JF tests were the most efficient of the three joint tests, in accordance with what we determined from 228 the single-study numerical simulation of MAGEE. 229 We assessed gene-sex interaction effects impacting WHR, using GEI and joint tests within the proposed

meta-analysis framework on WES data from the UK Biobank. GEI tests identified *COBLL1*, *HMGA1* and *VEGFB* that are already known to have loci with sex-dimorphic effects on WHR. The meta-analysis joint
tests identified 13 protein-coding regions, of which 10 had been previously linked to WHR in GWAS (27-

233 32), including COBLL1, HMGA1, VEGFB, PLXND1 and KIAA0408 that were reported to have sex-

specific genetic loci (27-29). The proposed meta-analysis GEI test did not reach significance for *PLXND1*

and *KIAA0408*, possibly due to the limited sample size. To identify rare variants that have effects

- 236 modified by the environment, extremely large sample sizes are required. Furthermore, we only examined
- 237 genetic variants in the exome, but noncoding regions may play a substantial role and may have integrated
- effects with protein-coding genes in complex diseases and traits (27, 35). Once more WES data from the
- 239 UK Biobank and more whole-genome sequencing (WGS) data become available from other large-scale
- consortia in the future, we expect that the meta-analysis will be used to identify more novel genetic
- 241 pathways contributing to a wide range of complex diseases.

242 Our summary statistics and meta-analysis framework have a few limitations. All participating studies in

the proposed meta-analysis must use a unified group definition file to ensure that the summary statistics

are generated consistently across studies. Although all component variants need not be present for all

studies, if different studies use different gene-level tests or group definition files, the summary statistics

- would be incompatible (3). In addition, in certain case-control studies, case/control ratios could be
- extremely unbalanced, leading to strong heterogeneity across studies (13). Future research could explore
- these extremely heterogeneous cases in further depth.

249 **Conclusions**

We developed efficient and powerful meta-analysis approaches to overcome the challenges associated with set-based GEI and joint tests for rare variants while allowing for sample relatedness. The metaanalysis leverages study-specific genomic summary statistics, eliminating the need to share individuallevel data, and is applicable to both quantitative and binary traits. In addition, the meta-analysis can accommodate heterogeneity among studies. These features allow the analysis of GEI effects across multiple large-scale sequencing studies and can improve the power in identification of novel risk factors for complex traits.

258 Methods

259 Modeling summary statistics

260 The meta-analysis of rare-variant GEI and joint tests involves two major steps. In the first step, we 261 perform a single-study analysis to calculate the summary statistics of the single-variant score vector and 262 covariance matrix for each variant. The second step consists of combining the summary statistics and 263 constructing the test statistic for the meta-analysis. The first step can be performed by using the MAGEE 264 software package. Below is a brief illustration of how to generate the summary statistics. 265 Suppose we have $m = 1, 2, \dots, M$ studies, first we need to generate the summary statistics for each 266 individual study. The full generalized linear mixed model (GLMM) for a single study m is in the 267 following form: $g(\mu_{mi}) = \mathbf{X}_{mi}\boldsymbol{\alpha}_m + \mathbf{G}_{mi}\boldsymbol{\beta}_m + \mathbf{K}_{mi}\boldsymbol{\gamma}_m + r_{mi} \quad (1)$ 268 where $g(\cdot)$ is the link function of μ_{mi} , which is the conditional mean of the phenotype of individual *i* in 269 study m. Typically, for a quantitative trait, $g(\cdot)$ is an identity function, while for a binary trait, $g(\cdot)$ is a 270 logit function. X_{mi} is a vector of p covariates including the intercept, and G_{mi} is a vector of q variants, 271 and K_{mi} is a vector of dq pairwise GEI terms for d environmental factors and q variants. Note that the 272 273 environmental factors are a subset of the covariates in X_{mi} . Accordingly, α_m is a $p \times 1$ vector for the 274 covariate effects, β_m is a $q \times 1$ vector for the genetic main effects, and γ_m is the $dq \times 1$ vector for GEI effects. The vector for the random intercept $\mathbf{r}_m = (r_1 r_2 \cdots r_N)^T \sim N(0, \sum_{l=1}^L \lambda_l \boldsymbol{\psi}_l)$, where N is the sample 275 size for study m, λ_l are the variance component parameters of L random effects, and $\boldsymbol{\psi}_l$ are $N \times N$ 276 277 known relatedness matrices.

Through MAGEE, we made statistical inference that the GEI effects test statistic in model (1) can be
approximated by fitting a global null model without adjusting for the genetic main effects. Specifically,
the global null models are fitted to each individual study as follows:

281
$$g(\mu_{mi}) = X_{mi}\alpha_m + r_{mi} \quad (2)$$

282 The score vector S_{G_m} for genetic main effects and GEI effects S_{K_m} are in the forms of S_{G_m} = $\boldsymbol{G}_{m}^{T}(\boldsymbol{y}_{m}-\boldsymbol{\hat{\mu}}_{0m})/\boldsymbol{\hat{\phi}}_{m}$ and GEI effects $\boldsymbol{S}_{K_{m}}=\boldsymbol{K}_{m}^{T}(\boldsymbol{y}_{m}-\boldsymbol{\hat{\mu}}_{0m})/\boldsymbol{\hat{\phi}}_{m}$, where $\boldsymbol{\hat{\mu}}_{0m}$ is a vector of fitted values 283 and $\hat{\phi}_m$ is the dispersion parameter estimated from model (2) in study *m*. Assuming the main effect of 284 genetic variants $\boldsymbol{\beta}_m$ are small in a null model with genetic main effects, but without GEI effects 285 $g(\mu_{mi}) = \mathbf{X}_{mi} \boldsymbol{\alpha}_m + \boldsymbol{G}_{mi} \boldsymbol{\beta}_m + r_{mi}$ (3), we can approximate the score vector for GEI effects accounting 286 for the genetic main effects by $\tilde{\mathbf{S}}_{K_m} \approx \mathbf{S}_{K_m} - \mathbf{K}_m^T \hat{\mathbf{P}}_m \mathbf{G}_m (\mathbf{G}_m^T \hat{\mathbf{P}}_m \mathbf{G}_m)^{-1} \mathbf{S}_{G_m}$ where $\mathbf{G}_m =$ 287 $(\boldsymbol{G}_{m1}^T \boldsymbol{G}_{m2}^T \dots \boldsymbol{G}_{mN}^T)^T$ is a $N \times q$ matrix of genetic variants, $\boldsymbol{X}_m = (\boldsymbol{X}_{m1}^T \boldsymbol{X}_{m2}^T \dots \boldsymbol{X}_{mN}^T)^T$ is a $N \times p$ matrix 288 of covariates, $\hat{P}_m = \hat{\Sigma}_m^{-1} - \hat{\Sigma}_m^{-1} X_m (X_m^T \hat{\Sigma}_m^{-1} X_m)^{-1} X_m^T \hat{\Sigma}_m^{-1}$ is an $N \times N$ projection matrix from the global 289 null model, where $\widehat{\Sigma}_m = \widehat{V}_m + \sum_{l=1}^L \hat{\lambda}_l \psi_l$, $\widehat{V}_m = \hat{\phi}_m I_N$ for quantitative traits and $diag\{\frac{1}{\widehat{\mu}_{0mi}(1-\widehat{\mu}_{0mi})}\}$ for 290 291 binary traits, which we estimate from model (2). 292 In the meta-analysis context, we save the single-variant scores of genetic main effects and GEI effects, S_{G_m} , S_{K_m} , as well as the covariance matrix for the score vectors $\mathbf{\Omega}_m = \begin{bmatrix} \mathbf{G}_m^T \widehat{\mathbf{P}}_m \mathbf{G}_m & \mathbf{G}_m^T \widehat{\mathbf{P}}_m \mathbf{K}_m \\ \mathbf{K}_m^T \widehat{\mathbf{P}}_m \mathbf{G}_m & \mathbf{K}_m^T \widehat{\mathbf{P}}_m \mathbf{K}_m \end{bmatrix} =$ 293 $\begin{bmatrix} \mathbf{V}_{G_m} & \mathbf{C}_m \\ \mathbf{C}_m^T & \mathbf{V}_{\kappa} \end{bmatrix}$ for each participant study *m*, where \mathbf{S}_{G_m} is a $q \times 1$ vector, \mathbf{S}_{K_m} is a $dq \times 1$ vector, $\mathbf{V}_{G_m} =$ 294 $\boldsymbol{G}_{m}^{T} \widehat{\boldsymbol{P}}_{m} \boldsymbol{G}_{m}$ is a $q \times q$ matrix, $\boldsymbol{V}_{K_{m}} = \boldsymbol{K}_{m}^{T} \widehat{\boldsymbol{P}}_{m} \boldsymbol{K}_{m}$ is a $dq \times dq$ matrix, and $\boldsymbol{C}_{m} = \boldsymbol{G}_{m}^{T} \widehat{\boldsymbol{P}}_{m} \boldsymbol{K}_{m}$ is a $q \times dq$ 295 matrix. As Ω_m is a large and symmetric matrix, we can save the lower triangle elements in a binary 296 format data to save space. Compared to saving the summary statistics as the double-precision floating 297 298 numbers that each takes 8 bytes, we used 4 bytes to save each floating-point number to further save the 299 space by 50%, without losing accuracy in the downstream meta-analysis. The test statistics are recovered using two combination strategies based on the assumption that genetic 300

301 effects are homogeneous or heterogeneous across studies.

302 Combine summary statistics assuming homogeneous effects

303 We combine the test statistics by summing the scores and their covariance matrices if we assume the

genetic effects are homogeneous across all the studies. For example, for $m = 1, 2 \dots M$ studies, we sum

305 the score statistics by
$$S_G = \sum_{m=1}^M S_{G_m}$$
, $S_K = \sum_{m=1}^M S_{K_m}$ and covariance matrix $\Omega = \sum_{m=1}^M \Omega_m =$

306
$$\begin{bmatrix} \sum_{m=1}^{M} \boldsymbol{V}_{G_m} & \sum_{m=1}^{M} \boldsymbol{C}_m \\ \sum_{m=1}^{M} \boldsymbol{C}_m^T & \sum_{m=1}^{M} \boldsymbol{V}_{K_m} \end{bmatrix} = \begin{bmatrix} \boldsymbol{V}_G & \boldsymbol{C} \\ \boldsymbol{C}^T & \boldsymbol{V}_K \end{bmatrix}$$
. Assuming all participating studies have q variants, \boldsymbol{S}_G is a $q \times 1$

307 vector, S_K is a $dq \times 1$ vector, V_G is a $q \times q$ matrix, V_K is a $dq \times dq$ matrix, and C is a $q \times dq$ matrix. In 308 practice, each variant does not need to be included in all the studies. If a variant is absent in study m, we 309 put a placeholder of 0 in place of this variant.

310 Combine summary statistics assuming heterogeneous effects

Suppose B ethnic groups are studied, some variants can have different allele frequencies depending on the 311 312 ancestry. Also, lifestyles (e.g., eating habits) and environmental exposures might modify the gene 313 differently, thus their effects on GEI might differ among ethnicities. By correctly accounting for 314 heterogeneity across studies, the power of the meta-analysis should be improved (4). Assuming 315 homogeneous within-ancestry but heterogeneous between-ancestry genetic and GEI effects, we sum the score statistics by $\boldsymbol{S}_{G} = (\sum_{m=1}^{M_{1}} \boldsymbol{S}_{G1_{m}}^{T} \sum_{m=1}^{M_{2}} \boldsymbol{S}_{G2_{m}}^{T} \cdots \sum_{m=1}^{M_{B}} \boldsymbol{S}_{GB_{m}}^{T})^{T}, \boldsymbol{S}_{K} =$ 316 $\left(\sum_{m=1}^{M_1} \boldsymbol{S}_{K1_m}^T \sum_{m=1}^{M_2} \boldsymbol{S}_{K2_m}^T \cdots \sum_{m=1}^{M_B} \boldsymbol{S}_{KB_m}^T\right)^T \text{ and the covariance matrices by } \boldsymbol{\Omega} = diag\left\{\sum_{m=1}^{M_b} \boldsymbol{\Omega}_{b_m}\right\} \text{ over } \boldsymbol{\Omega}_{km}$ 317 the studies, where S_{Gb_m} , S_{Kb_m} , and Ω_{b_m} are the genetic score vector, GEI score vector, and covariance 318 matrix of study m in ethnic group b, respectively. M_b is the number of studies in ethnic group b and 319 $\sum_{b=1}^{B} M_b = M. \ \mathbf{\Omega} \text{ can be partitioned to } diag \left\{ \sum_{m=1}^{M_b} \begin{bmatrix} \mathbf{V}_{Gb_m} & \mathbf{C}_{b_m} \\ \mathbf{C}_{h\dots}^T & \mathbf{V}_{Kh\dots} \end{bmatrix} \right\}, \text{ and the variance matrices for } \mathbf{V}_{Kh\dots} = \mathbf{V}_{Kh\dots} = \mathbf{V}_{Kh\dots}$ 320 genetic effects, GEI effects, and the covariance matrix of genetic and GEI effects are V_G = 321 $diag\{\sum_{m=1}^{M_b} V_{Gb_m}\}, V_K = diag\{\sum_{m=1}^{M_b} V_{Kb_m}\}, \text{ and } C = diag\{\sum_{m=1}^{M_b} C_{b_m}\}, \text{ respectively. The lengths are } C_{M_b} = diag\{\sum_{m=1}^{M_b} C_{M_b}, \sum_{m=1}^{M_b} C_{M_b},$ 322 323 then Bq for S_G and Bdq for S_K . V_G , V_K , and C are block-diagonal matrices with B blocks of $q \times q$, $dq \times dq$, and $q \times dq$ sub-matrices respectively for each ancestry. 324

325 GEI tests

In the MAGEE framework (10), we developed two GEI tests: interaction variance component (IV) testand interaction hybrid test using Fisher's method (IF). The same GEI tests can be reconstructed for the

meta-analysis from the combined score vectors and the covariance matrices. IV test assumes the overall GEI effects $\gamma \sim N(0, \tau W_K^2)$, for which the test statistic is

$$T_{\nu} = \tilde{S}_{K}^{T} W_{K} W_{K} \tilde{S}_{K}$$

331 where $\tilde{\mathbf{S}}_K \approx \mathbf{S}_K - \mathbf{C}^T \mathbf{V}_G^{-1} \mathbf{S}_G$ and \mathbf{W}_K is a predefined diagonal weight matrix for interaction. T_{γ} follows a

distribution of $\sum_{j=1}^{Bdq} \xi_{\gamma,j} \chi_{1,j}^2$, where $\chi_{1,j}^2$ are independent chi-square distributions with 1 degree of

freedom (df), and $\xi_{V,i}$ are the eigenvalues of $W_K \Lambda W_K$, where $\Lambda = V_K - C^T V_G^{-1} C$.

334 W_K can be flexibly determined using annotation information or MAFs in the combined studies without

having to access the individual-level data (36-38). One of the most popular ways to add weight to variants

based on MAF is to use a beta density function with parameters 1 and 25 for the MAF (6). The dimension

of W_K is $Bdq \times Bdq$, in which B = 1 if we combine the summary statistics assuming homogeneous

338 genetic effects.

339 IF test assumes the overall GEI effects $\gamma \sim N(W_K \mathbf{1}_{Bdq}\gamma_0, \tau W_K^2)$, where $\mathbf{1}_{Bdq}$ is a vector of 1's with 340 length Bdq. To test for $H_0: \gamma_0 = \tau = 0$, we need two test statistics, T_{γ_0} for the burden effects γ_0 and T_{τ} for 341 the variance component effects τ . The burden effects test statistic

342 $T_{\gamma_0} = \tilde{\mathbf{S}}_K^T \mathbf{W}_K \mathbf{1}_{Bdq} \mathbf{1}_{Bdq}^T \mathbf{W}_K \tilde{\mathbf{S}}_K$

follows the distribution of $\xi_{\gamma_0} \chi_1^2$ under the null hypothesis $H_0: \gamma_0 = 0$, where $\xi_{\gamma_0} = \mathbf{1}_{Bdq}^T \mathbf{W}_K \Lambda \mathbf{W}_K \mathbf{1}_{Bdq}$. 344 The variance component effects test statistic is

 $T_{\tau} = \tilde{\boldsymbol{S}}_{KV}^T \boldsymbol{W}_K \boldsymbol{W}_K \tilde{\boldsymbol{S}}_{KV},$

346 where $\tilde{S}_{KV} \approx \tilde{S}_K - \Lambda W_K \mathbf{1}_{Bdq} (\mathbf{1}_{Bdq}^T W_K \Lambda W_K \mathbf{1}_{Bdq})^{-1} \mathbf{1}_{Bdq}^T W_K \tilde{S}_K. T_{\tau}$ follows the distribution of

347 $\sum_{j=1}^{Bdq} \xi_{\tau,j} \chi_{1,j}^2$ under the null hypothesis $H_0: \tau = 0$, where $\xi_{\tau,j}$ are eigenvalues for $W_K \Lambda W_K -$

348 $W_K \Lambda W_K \mathbf{1}_{Bdq} (\mathbf{1}_{Bdq}^T W_K \Lambda W_K \mathbf{1}_{Bdq})^{-1} \mathbf{1}_{Bdq}^T W_K \Lambda W_K$. Since T_{γ_0} and T_{τ} are asymptotically independent

349 (proved by Wang *et al.* (10)), a Fisher's combination (39) can be used to find the *p* value for the IF test:

350 $p_{IF} = P(\chi_4^2 > -2 \log p_{\gamma_0} - 2 \log p_{\tau})$, where p_{γ_0} and p_{τ} are *p* values from the burden-type test $H_0: \gamma_0 =$ 351 0 (under the assumption $\tau = 0$) and the adjusted variance component test $H_0: \tau = 0$, respectively.

352 Joint tests

In the joint test, which evaluates both genetic effects and GEI effects, β and γ , the test statistics for β 353 354 must also be reconstructed after summing the summary statistics across all studies. A meta-analysis 355 framework for genetic main effects tests has been developed by SMMAT, which supports both SKAT test 356 and unified burden and SKAT test. Wang et al. (10) has shown that those test statistics for the genetic 357 main effects and the GEI test are mutually independent. Assume that the p value from the meta-analysis 358 SKAT is p_{MV} and the p value from the meta-analysis IV test is p_{IV} , we can combine them through Fisher's method as $p_{JV} = P(\chi_4^2 > -2 \log p_{MV} - 2 \log p_{IV})$ for the joint variance component (JV) test. 359 Similarly, assuming p_{β_0} and p_{σ} are the p values from the hybrid genetic main effects meta-analysis, we 360 can combine them with their GEI test counterparts p_{γ_0} and p_{τ} through $p_{JF} = P(\chi_8^2 > -2 \log p_{\beta_0} - 2 \log p_{\beta_0})$ 361 $2\log p_{\sigma} - 2\log p_{\gamma_0} - 2\log p_{\tau}$), which is the joint hybrid test using Fisher's method (JF). Alternatively, 362 we can combine the *p* values for genetic effects separately by $p_{MF} = P(\chi_4^2 > -2 \log p_{\beta_0} - 2 \log p_{\sigma})$, 363 and then combine the main effects and GEI p values by $p_{ID} = P(\chi_4^2 > -2 \log p_{MF} - 2 \log p_{IF})$, which 364 365 is the joint hybrid test using double Fisher's procedures (JD).

366 Numerical Simulations

Using related individuals from the same population and different populations, we conducted simulation
studies with two purposes: (1) benchmarking *p* values from the meta-analysis to the pooled analysis of
individual-level data from MAGEE; and (2) evaluating the performance of each test under the conditions
of heterogeneous genetic influence across populations.

We simulated the genotype replicates in two different populations using MS (40) and prepared two

scenarios based on the two populations. In scenario 1, we simulated 100,000 individuals from the same

population, which included 50,000 parents and 50,000 children in a family relatedness pattern with a

| 374 | kinship matrix of | 0.5 0.0 0.25 0.25 0.0 0.5 0.25 0.25 0.25 0.25 0.5 0.25 0.25 0.25 0.5 0.5 | . The 100,000 samples were split into two studies of 50,000 |
|-----|-------------------|---|---|
|-----|-------------------|---|---|

individuals (12,500 families) each, and the covariates were the same in the two studies. In scenario 2, we

simulated 2 populations with a migration rate of 10. Each population had 50,000 individuals, including

377 25,000 parents and 25,000 children who were related to each other in the same way as scenario 1. The

378 covariates in these two studies were different. The simulation scenarios and covariates setup for each

379 study are summarized in Table 2. Each scenario had 1,000 genotype replicates of 100 variants in a group.

Both qualitative and binary traits were simulated, and the following section describes the details for each

381 simulation.

382 Table 2. Summary of simulation scenarios.

| | Population 1 | Population 2 | Covariates | | | |
|--|--------------|--------------|---------------|--|--|--|
| Scenario 1: homoger | | | | | | |
| Study 1 | 50,000 | 0 | Age, sex, BMI | | | |
| Study 2 | 50,000 | 0 | Age, sex, BMI | | | |
| Scenario 2: heterogeneous genetic main effects and GEI effects | | | | | | |
| Study 1 | 50,000 | 0 | Age, sex, BMI | | | |
| Study 2 | 0 | 50,000 | Sex, BMI | | | |

383

384 Comparison of *p* values and power

We simulated 10 phenotype replicates per genotype replicate. In each study, the quantitative traits of

individual *j* in family *i* were simulated from

387
$$y_{ij} = \alpha_1 Age_{ij} + \alpha_2 Sex_{ij} + \alpha_3 BMI_{ij} + \sum_{t=1}^q \beta_t (G_{ijt} - \overline{G_t}) + \sum_{t=1}^q \gamma_t (K_{ijt} - \overline{K_t}) + r_{ij} + \varepsilon_{ij},$$

388 where $Age_{ij} \sim N(50, 5)$ for parents and $Age_{ij} \sim N(50, 5)$ for children, $Sex_{ij} \sim Bernoulli(0.5)$ for both

parents and children, BMI for family *i* follows a distribution with heritability (41) of 0.75 (44) $BMI_i \sim$

| 390 | $N(\begin{bmatrix} 25\\25\\25\\25\\25\end{bmatrix}, \begin{bmatrix} 4.0 & 0.0 & 1.5 & 1.5\\0.0 & 4.0 & 1.5 & 1.5\\1.5 & 1.5 & 4.0 & 1.5\\1.5 & 1.5 & 1.5 & 4.0 \end{bmatrix}$ |), the random effects for family $i r_i \sim N($ | 0 0 0 0 | , | 1.0 0.0 0.5 0.5 | 0.0 1.0 0.5 0.5 | 0.5 0.5 1.0 0.5 | 0.5 0.5 0.5 1.0 |), and th | ie |
|-----|---|--|------------------|---|--------------------------|--------------------------|--------------------------|--------------------------|-----------|----|
|-----|---|--|------------------|---|--------------------------|--------------------------|--------------------------|--------------------------|-----------|----|

random error $\varepsilon_{ij} \sim N(0, 1)$. G_{ijt} was the *t*-th genetic variant for individual *j* in family *i* and $\overline{G_t}$ was the

mean of the t-th variant, and $K_{ijt} = (G_{ijt} - \overline{G_t})(BMI_{ij} - \overline{BMI})$ was the GEI term for the *t*-th variant with BMI for individual *j* from family *i* and $\overline{K_t}$ was the mean of the *t*-th interaction term in that study.

394 The binary traits were simulated using a logistic regression model from

395
$$\log\left(\frac{P(y_{ij}=1)}{1-P(y_{ij}=1)}\right) = \alpha_0 + \alpha_1(Age_{ij} - \overline{Age}) + \alpha_2(Sex_{ij} - \overline{Sex}) + \alpha_3(BMI_{ij} - \overline{BMI}) + \alpha_3(BMI_{ij} - \overline{BMI})$$

$$\sum_{t=1}^{q} \beta_t (G_{ijt} - \overline{G_t}) + \sum_{t=1}^{q} \gamma_t (K_{ijt} - \overline{K_t}) + r_{ij},$$

where *Age*, *Sex*, *BMI*, and the random effects for family *i* r_i followed the same distribution as the quantitative traits, and \overline{Age} , \overline{Sex} , and \overline{BMI} were the population means in each study, α_0 was set to $\log \frac{0.4}{1-0.4}$ representing a prevalence rate of 0.4. G_{ijt} , $\overline{G_t}$ and the calculation of K_{ijt} and $\overline{K_t}$ were the same as the quantitative traits.

401 For scenario 1, the parameters for age, sex, and BMI were $\alpha_1 = 0.1$, $\alpha_2 = 0.2$, and $\alpha_3 = 0.1$, the same 402 for study 1 and study 2. The effect sizes β_t for G and γ_t for GEI were also the same across in both 403 studies. In scenario 2, the parameters for the covariates in study 1 were the same as those for scenario 1, while the parameters in study 2 were $\alpha_1 = 0$, $\alpha_2 = 0.4$, and $\alpha_3 = 0.12$, so that age was excluded from 404 405 the covariates. In addition, the effect sizes for G and GEI effects were different between the 2 studies in scenario 2. Specifically, the effect sizes of a variant β_t and γ_t were proportional to its MAF as 406 $clog_{10}(MAF_t)$, where c represents a constant. Detailed information of the constants c for β_t and γ_t in 407 each simulation can be found in supplemental Table S1 for the p value benchmark, supplemental Table 408 409 S2 for the quantitative trait power comparison, and supplemental Table S3 for the binary trait power 410 comparison.

For the *p* value benchmark, we used different parameters for three different sample sizes. In total, 20% of the variants were randomly selected as causal, which included 10% positive effects and 10% negative effects. For power comparisons, the same parameters were used with different sample sizes, but different parameters were used for GEI and joint tests. We used two approaches to indicate the proportion of causal variants: (1) we randomly chose 20% of causes, among which 10% were positive and 10% were negative;

(2) we randomly selected 20% of causes, among which 16% were positive and 4% were negative. The
gene-BMI interaction was tested both for binary and quantitative traits. According to Wu *et al.* (6), we
used a beta density weight function with parameters 1 and 25 on the MAF, so that rare variants had a
higher weight than common variants.

420 Application to UK Biobank whole exome sequencing data

421 We used the UK Biobank (42) whole exome sequencing (WES) data as an example of our proposed meta-422 analysis. The UK Biobank has released the first tranche of WES data containing 49,959 samples in March 423 2019. The second tranche of WES data was released in October 2020 with 200,632 samples (including the 424 samples in the first tranche). We divided the dataset in the second tranche by the first and second batches 425 to meta-analyze the two datasets because there may be measurement errors or batch-specific 426 heterogeneities due to differences in quality control procedures. After excluding the subjects with missing 427 sex information, missing age, BMI or WHR, non-white British, and those who have withdrawn from the 428 study, a total of 43,190 subjects were eligible for batch 1 (23,372 women and 19,818 men), and 132,058 429 subjects were eligible for batch 2 (72,961 women and 59,097 men). The age distribution was mean = 430 56.95 (sd = 7.89) in batch 1 and mean = 56.75 (sd = 8.04) in batch 2. The BMI distribution was mean = 431 27.40 (sd = 4.77) in batch 1 and mean = 27.34 (sd = 4.70) in batch 2.We tested for gene-by-sex 432 interaction effects on WHR at the gene-level for the two batches. We first fitted a linear mixed model (43) adjusting for sex, age, age² and the top ten ancestry principal components (PCs) for each batch using 433 glmmkin function from the GMMAT package, 434

435

$WHR \sim sex + age + age^2 + BMI + PC1 + PC2 + \dots + PC10.$

The relatedness matrix was constructed using the kinship coefficients computed by KING software (44)
for third-degree and closer relatives, provided by the UK Biobank (see UK Biobank Resource 531).

We used the genotype data generated by the Functionally Equivalent (FE) pipeline (45). The variantgroups were defined as protein-coding regions for the WES data and a total of 19,449 protein-coding

regions with 17,549,650 variants were available for analysis. MAGEE was used to generate the score

441 statistics and the covariance matrices for each batch. In the next step, we combined and meta-analyzed the 442 scores and covariance matrices for the two batches, assuming homogeneous genetic effects. As IF test was more powerful than the IV test, and JF test was slightly more powerful than JV and JD tests in our 443 power simulations, in the UK Biobank WES data analysis we reported IF and JF test p values as the GEI 444 445 and joint test results, respectively. The meta-analysis excluded variants with a minor allele count (MAC) 446 less than 5, or with a genotype missing rate greater than 5% in the combined dataset, and 18,668 protein-447 coding regions with 2,328,550 variants passed these filters. We applied a beta density weight function with parameters 1 and 25 on the MAF. In addition, we compared the meta-analysis results to the results of 448 449 a joint analysis pooling all the individual-level data using MAGEE. For protein-coding regions that reached the Bonferroni-corrected significance level of $0.05/18,668 = 2.7 \times 10^{-6}$, we also performed 450 conditional analysis by adjusting for variants in the region that had a single variant joint test p value less 451 452 than 5.0×10^{-8} , MAF greater than 1% and genotype missing rate less than 5%. Both the genetic main effect 453 and gene-sex interaction terms of significant single variants were included in the conditional analysis. 454

455 **References**

(1) Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005;6(4):287-298.

457 (2) Thomas D. Gene–environment-wide association studies: emerging approaches. Nat Rev Genet
458 2010;11(4):259-272.

(3) Hu Y, Berndt SI, Gustafsson S, Ganna A, Hirschhorn J, North KE, et al. Meta-analysis of gene-level
associations for rare variants based on single-variant statistics. Am J Hum Genet 2013;93(2):236-48.

(4) Lee S, Abecasis GR, Boehnke M, Lin X. Rare-Variant Association Analysis: Study Designs and
Statistical Tests. Am J Hum Genet 2014;95(1):5-23.

463 (5) Li B, Leal SM. Methods for Detecting Associations with Rare Variants for Common Diseases:
464 Application to Analysis of Sequence Data. The American Journal of Human Genetics 2008;83(3):311465 321.

(6) Wu M, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-Variant Association Testing for Sequencing Data
with the Sequence Kernel Association Test. The American Journal of Human Genetics 2011;89(1):82-93.

- (7) Price AL, Kryukov GV, de Bakker PIW, Purcell SM, Staples J, Wei L, et al. Pooled Association Tests
 for Rare Variants in Exon-Resequencing Studies. Am J Hum Genet 2010;86(6):832-838.
- 470 (8) Chen H, Meigs JB, Dupuis J. Incorporating Gene-Environment Interaction in Testing for Association
- 471 with Rare Genetic Variants. Hum Hered 2014;78(2):81-90.
- 472 (9) Su Y, Di C, Hsu L. A unified powerful set-based test for sequencing data analysis of GxE interactions.
 473 Biostatistics (Oxford, England) 2017;18(1):119.
- 474 (10) Wang X, Lim E, Liu C, Sung YJ, Rao DC, Morrison AC, et al. Efficient gene–environment
- interaction tests for large biobank-scale sequencing studies. Genet Epidemiol 2020;44(8):908-923.
- (11) Kraft P, Yen Y, Stram DO, Morrison J, Gauderman WJ. Exploiting Gene-Environment Interaction to
 Detect Genetic Associations. Hum Hered 2007;63(2):111-119.
- 478 (12) Sung YJ, Winkler TW, Manning AK, Aschard H, Gudnason V, Harris TB, et al. An Empirical

479 Comparison of Joint and Stratified Frameworks for Studying $G \times E$ Interactions: Systolic Blood Pressure 480 and Smoking in the CHARGE Gene-Lifestyle Interactions Working Group. Genet Epidemiol

- 481 2016;40(5):404-415.
- (13) Lee S, Teslovich TM, Boehnke M, Lin X. General Framework for Meta-analysis of Rare Variants in
 Sequencing Association Studies. Am J Hum Genet 2013;93(1):42-53.
- (14) Liu DJ, Peloso GM, Zhan X, Holmen OL, Zawistowski M, Feng S, et al. Meta-analysis of gene-level
 tests for rare variant association. Nat Genet 2014;46(2):200-204.
- (15) Feng S, Liu D, Zhan X, Wing MK, Abecasis GR. RAREMETAL: fast and powerful meta-analysis
 for rare variants. Bioinformatics 2014;30(19):2828-2829.
- (16) Yang J, Chen S, Abecasis G. Improved score statistics for meta-analysis in single-variant and genelevel association studies. Genet Epidemiol 2018;42(4):333-343.
- 490 (17) Tang Z, Lin D. MASS: meta-analysis of score statistics for sequencing studies. Bioinformatics
 491 2013;29(14):1803-1805.
- (18) He Z, Xu B, Lee S, Ionita-Laza I. Unified Sequence-Based Association Tests Allowing for Multiple
 Functional Annotations and Meta-analysis of Noncoding Variation in Metabochip Data. Am J Hum Genet
 2017;101(3):340-352.
- (19) Ka J, Lee J, Kim Y, Oh B, Park T. Meta-Qtest: meta-analysis of quadratic test for rare variants. BMC
 medical genomics; BMC Med Genomics 2019;12:102-102.
- 497 (20) Chen H, Huffman JE, Brody JA, Wang C, Lee S, Li Z, et al. Efficient Variant Set Mixed Model
- Association Tests for Continuous and Binary Traits in Large-Scale Whole-Genome Sequencing Studies.
 The American Journal of Human Genetics 2019;104(2):260-274.
- (21) Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
 scans. Bioinformatics 2010;26(17):2190-2191.

- 502 (22) Wang J, Liu Q, Pierce BL, Huo D, Olopade OI, Ahsan H, et al. A meta-analysis approach with
- filtering for identifying gene-level gene–environment interactions. Genet Epidemiol 2018;42(5):434-446.
- 504 (23) Jin X, Shi G. Variance-Component-Based Meta-Analysis of Gene-Environment Interactions for Rare
 505 Variants. G3 (Bethesda, Md.) 2021.
- (24) Aschard H, Hancock DB, London SJ, Kraft P. Genome-Wide Meta-Analysis of Joint Tests for
 Genetic and Gene-Environment Interaction Effects. Hum Hered 2010;70(4):292-300.
- 508 (25) Manning AK, LaValley M, Liu C, Rice K, An P, Liu Y, et al. Meta-analysis of gene-environment
 509 interaction: joint estimation of SNP and SNP × environment regression coefficients. Genet Epidemiol
 510 2011;35(1):11-18.
- (26) Bland JM, Altman DG. Multiple Significance Tests: The Bonferroni Method. BMJ: British Medical
 Journal 1995;310(6973):170-170.
- (27) Lumish HS, O'Reilly M, Reilly MP. Sex Differences in Genomic Drivers of Adipose Distribution
 and Related Cardiometabolic Disorders: Opportunities for Precision Medicine. Arterioscler Thromb Vasc
 Biol 2020;40(1):45-60.
- (28) Shungin D, Winkler TW, Croteau-Chonka D, Ferreira T, Locke AE, Mägi R, et al. New genetic loci
 link adipose and insulin biology to body fat distribution. Nature 2015;518(7538):187-U378.
- (29) Justice AE, Karaderi T, Highland HM, Young KL, Graff M, Lu Y, et al. Protein-coding variants
 implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Nat Genet
 2019;51(3):452-469.
- 521 (30) Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, et al. Meta-analysis
- identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis
 of fat distribution. Nat Genet 2010;42(11):949-U160.
- (31) Lotta LA, Wittemans L, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of genetic variants
 related to gluteofemoral vs abdominal fat distribution With type 2 diabetes, coronary disease, and
 cardiovascular risk factors. 2018.
- 527 (32) Zhu Z, Guo Y, Shi H, Liu C, Panganiban RA, Chung W, et al. Shared genetic and experimental links
 528 between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol
 529 2020;145(2):537-549.
- (33) Hill AVS, Allsopp CEM, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common West
 African HLA antigens are associated with protection from severe malaria. Nature 1991;352(6336):595600.
- (34) Tang Z, Lin D. Meta-Analysis of Sequencing Studies With Heterogeneous Genetic Associations.
 Genet Epidemiol 2014;38(5):389-401.
- 535 (35) Lee YH. Meta-analysis of genetic association studies. Annals of laboratory medicine
- **536** 2015;35(3):283.

- (36) Kircher M, Witten DM, Jain P, O'Roak B,J., Cooper GM, Shendure J. A general framework for
 estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46(3):310-315.
- (37) Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of
 variants throughout the human genome. Nucleic Acids Res 2019;47:D886-D894.
- (38) Rogers MF, Shihab HA, Mort M, Cooper DN, Gaunt TR, Campbell C. FATHMM-XF: accurate
 prediction of pathogenic point mutations via extended features. Bioinformatics 2018;34(3):511-513.
- (39) Fisher RA. Statistical Methods for Research Workers. Second Edition, Revised and enlarged.
 Edinburgh: Oliver and Boyd. Journal of Comparative Pathology and Therapeutics 1928;41:261-262.
- (40) Hudson RR. Generating samples under a Wright–Fisher neutral model of genetic variation.
 Bioinformatics 2002;18(2):337-338.
- 547 (41) Elks CE, Den Hoed M, Zhao JH, Sharp SJ, Wareham NJ, Loos RJF, et al. Variability in the
- heritability of body mass index: a systematic review and meta-regression. Frontiers in endocrinology
 2012;3:29.
- (42) Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
 with deep phenotyping and genomic data. Nature 2018;562(7726):203-209.
- (43) Conomos MP, Laurie CA, Stilp AM, Gogarten SM, Mchugh CP, Nelson SC, et al. Genetic Diversity
 and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community
 Health Study/Study of Latinos. Am J Hum Genet 2016;98(1):165.
- (44) Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W. Robust relationship inference
 in genome-wide association studies. Bioinformatics 2010;26(22):2867-2873.
- 557 (45) Regier AA, Farjoun Y, Larson DE, Krasheninina O, Kang HM, Howrigan DP, et al. Functional
- equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human
- genetics projects. Nature communications 2018;9(1):4038.
- 560

561 **Declarations**

562 Ethics approval and consent to participate

- 563 This study was approved by the Institutional Review Board (IRB) of The University of Texas Health
- 564 Science Center at Houston (UTHealth) with project number HSC-SPH-18-0466. Waiver of informed
- consent was granted.
- 566 Availability of data and materials

- 567 The individual-level data that support the findings of this study are available upon application to the UK
- 568 Biobank (https://www.ukbiobank.ac.uk/register-apply/).
- 569 The method is implemented in R package MAGEE, available at https://github.com/large-scale-gxe-
- 570 methods/MAGEE.
- 571 Competing interests
- 572 The authors declare that they have no competing interests.
- 573 Funding
- 574 This research was supported by National Institutes of Health (NIH) grant R01 HL145025.
- 575 Authors' Information
- 576 Affiliations
- 577 Department of Biostatistics and Data Science, School of Public Health, The University of Texas
- 578 Health Science Center at Houston, Houston, TX, USA
- 579 Xinyu Wang
- 580 Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental
- 581 Sciences, School of Public Health, The University of Texas Health Science Center at Houston,
- 582 Houston, TX, USA
- 583 Duy T. Pham, Cong Pan & Han Chen
- 584 Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital,
- 585 Boston, MA, USA
- 586 Kenneth E. Westerman & Alisa K. Manning
- 587 Metabolism Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 588 Kenneth E. Westerman & Alisa K. Manning

- 589 Department of Medicine, Harvard Medical School, Boston, MA, USA
- 590 Kenneth E. Westerman & Alisa K. Manning
- 591 Center for Precision Health, School of Public Health and School of Biomedical Informatics, The
- 592 University of Texas Health Science Center at Houston, Houston, TX, USA
- 593 Han Chen
- 594 *Corresponding author*
- 595 Correspondence to: Han Chen

596 Acknowledgements

- 597 This research has been conducted using the UK Biobank Resource under Application Number 42646.
- 598 This work was supported by National Institutes of Health (NIH) grant R01 HL145025.